Never underestimate the FOMO effect. If BIT225 is an effective treatment, and more effective than the existing standard of care (even if a little) they wouldn't really want to see a competitor take it over. They've seen enough clinical trials come and go, with experience you get to understand the potential of where a new treatment will fit in, and the likelihood of it passing all the clinical trials.
